{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:54:46Z","timestamp":1781628886117,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["222983\/Z\/21\/Z"],"award-info":[{"award-number":["222983\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>COVID-19 predisposes patients to secondary infection, resulting in increased mortality worldwide. It is thus crucial to identify the causes of secondary infection and their clinical outcomes to devise future prevention and control strategies. This study aimed to report the clinical and microbiological features of bacterial and fungal secondary infections in severe COVID-19 patients during the peak of the pandemic in Vietnam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We collected data from 3,789 confirmed COVID-19 patients hospitalized at the Hospital for Tropical Diseases in Ho Chi Minh City between 2020 and 2021. Demographics, infection pathogens, treatment characteristics, and patient outcomes were recorded. Univariate and multivariate analyses were performed to identify risk factors associated with mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Microbiologically confirmed secondary infection was identified in 17.7% (651\/3,682) of hospitalized COVID-19 patients. The most frequent comorbidities were cardiovascular diseases (74.9%), hypertension (65.9%), and diabetes (54.5%). The overall survival rate was 83.5% (3,075\/3,682), highest in patients without secondary infection (97.2%), and dropped dramatically to 35.6% in those with microbiologically confirmed secondary infection. Out of 2,649 pathogens identified, Gram-negative bacteria accounted for 53.8% of isolates, followed by fungi (32.5%) and Gram-positive bacteria (13.7%). Notably, the predominant bacterial (\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      ,\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                      ,\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      ) and fungal pathogens (\n                      <jats:italic>C. tropicalis<\/jats:italic>\n                      ,\n                      <jats:italic>C. albicans<\/jats:italic>\n                      ) exhibited high resistance rates to last-resort antibiotics (carbapenems, colistin) and antifungal drugs (fluconazole), respectively. Regression analyses found that secondary infection, older age, chronic kidney disease, cardiovascular disease and mechanical ventilation were the independent predictors of mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Secondary infection in COVID-19 patients was predominantly caused by highly resistant Gram-negative bacteria, and was associated with older patients who had comorbidities and underwent invasive procedures. Patients with secondary infection experienced higher mortality. Our work underscores the need for strengthening infection prevention measures and antibiotic stewardship programs to prevent nosocomial infections and better prepare for future epidemics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12479-w","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:00:42Z","timestamp":1767150042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Secondary infection in severe COVID-19 patients: clinical and microbial patterns at a tertiary hospital in Vietnam"],"prefix":"10.1186","volume":"26","author":[{"given":"Pham Hong","family":"Anh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau","family":"Vinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Phu Huong","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Quang","family":"Minh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Thi Quynh","family":"Ngan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huynh Phuong","family":"Thao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Thu Si","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Thanh","family":"Dung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeonji","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham Thanh","family":"Duy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"12479_CR1","unstructured":"WHO Global Report. COVID-19 epidemiological update. https:\/\/www.who.int\/publications\/m\/item\/covid-19-epidemiological-update-edition-167 (2024)."},{"key":"12479_CR2","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jiph.2023.07.005","volume":"16","author":"AS Suleiman","year":"2023","unstructured":"Suleiman AS, et al. A meta-meta-analysis of co-infection, secondary infections, and antimicrobial resistance in COVID-19 patients. J Infect Public Health. 2023;16:1562\u201390.","journal-title":"J Infect Public Health"},{"key":"12479_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/14787210.2023.2299387","volume":"22","author":"Z Ul Mustafa","year":"2024","unstructured":"Ul Mustafa Z, et al. Bacterial co-infections, secondary infections and antimicrobial use among hospitalized COVID-19 patients in the sixth wave in pakistan: findings and implications. Expert Rev Anti Infect Ther. 2024;22:229\u201340.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"12479_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/cid\/ciaa653","volume":"73","author":"KYL Chua","year":"2021","unstructured":"Chua KYL, et al. Co-infection, secondary infection, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study. Clin Infect Dis. 2021;73:487\u201396.","journal-title":"Clin Infect Dis"},{"key":"12479_CR5","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.cmi.2020.07.016","volume":"26","author":"BJ Langford","year":"2020","unstructured":"Langford BJ, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"12479_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12941-023-00625-8","volume":"22","author":"A Pa\u0142ka","year":"2023","unstructured":"Pa\u0142ka A, et al. Secondary bacterial infections & extensively drug-resistant bacteria among COVID-19 hospitalized patients at the university hospital in Krak\u00f3w. Ann Clin Microbiol Antimicrob. 2023;22:1\u201310.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"12479_CR7","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.2147\/IDR.S299774","volume":"14","author":"S Vijay","year":"2021","unstructured":"Vijay S, et al. Secondary infections in hospitalized COVID-19 patients: Indian experience. Infect Drug Resist. 2021;14:1893\u2013903.","journal-title":"Infect Drug Resist"},{"key":"12479_CR8","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3201\/eid2810.220321","volume":"28","author":"A Wolfensberger","year":"2022","unstructured":"Wolfensberger A, et al. Nosocomial COVID-19 incidence and secondary attack rates among patients of tertiary care Center, Zurich, Switzerland. Emerg Infect Dis. 2022;28:2087\u201390.","journal-title":"Emerg Infect Dis"},{"key":"12479_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpubh.2021.709067","volume":"9","author":"LHN Minh","year":"2021","unstructured":"Minh LHN, Quan K, Le N, Khanh TN, P. N. Q., Huy NT. COVID-19 timeline of vietnam: important milestones through four waves of the pandemic and lesson learned. Front Public Health. 2021;9:1\u20134.","journal-title":"Front Public Health"},{"key":"12479_CR10","unstructured":"Vietnam ministry of health - ministry of health portal on COVID-19 pandemic."},{"key":"12479_CR11","doi-asserted-by":"crossref","unstructured":"Bui HM et al. Movement restrictions, vaccine coverage, and reduction of the COVID-19 incidence rate in the fourth wave of the pandemic: analysis results from 63 provinces in Vietnam. Front Public Health 2023:10.","DOI":"10.3389\/fpubh.2022.988107"},{"key":"12479_CR12","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1016\/S2666-5247(21)00090-2","volume":"2","author":"CD Russell","year":"2021","unstructured":"Russell CD, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. 2021;2:e354\u201365.","journal-title":"Lancet Microbe"},{"key":"12479_CR13","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1128\/CMR.00062-05","volume":"19","author":"KK Hall","year":"2006","unstructured":"Hall KK, Lyman JA. Updated review of blood culture contamination. Clin Microbiol Rev. 2006;19:788\u2013802.","journal-title":"Clin Microbiol Rev"},{"key":"12479_CR14","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1086\/513953","volume":"26","author":"JG Bartlett","year":"1998","unstructured":"Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-Acquired pneumonia in adults: guidelines for management. Clin Infect Dis. 1998;26:811\u201338.","journal-title":"Clin Infect Dis"},{"key":"12479_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"12479_CR16","doi-asserted-by":"crossref","unstructured":"Musuuza JS et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and metaanalysis. PLoS ONE 2021:16.","DOI":"10.1371\/journal.pone.0251170"},{"key":"12479_CR17","doi-asserted-by":"publisher","unstructured":"Langford BJ et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clinical Microbiology and Infection 2020;26:1622\u20131629 Preprint at https:\/\/doi.org\/10.1016\/j.cmi.2020.07.016.","DOI":"10.1016\/j.cmi.2020.07.016"},{"key":"12479_CR18","doi-asserted-by":"publisher","unstructured":"Suleiman AS et al. A meta-meta-analysis of co-infection, secondary infections, and antimicrobial resistance in COVID-19 patients. Journal of Infection and Public Health. 2023;16:1562\u20131590 Preprint at https:\/\/doi.org\/10.1016\/j.jiph.2023.07.005.","DOI":"10.1016\/j.jiph.2023.07.005"},{"key":"12479_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cmi.2020.10.021","volume":"27","author":"M Ripa","year":"2021","unstructured":"Ripa M, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect. 2021;27:451\u20137.","journal-title":"Clin Microbiol Infect"},{"key":"12479_CR20","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/S2666-5247(22)00355-X","volume":"4","author":"BJ Langford","year":"2023","unstructured":"Langford BJ, et al. Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis. Lancet Microbe. 2023;4:e179\u201391.","journal-title":"Lancet Microbe"},{"key":"12479_CR21","doi-asserted-by":"publisher","first-page":"e13798","DOI":"10.1111\/myc.13798","volume":"67","author":"K Srisurapanont","year":"2024","unstructured":"Srisurapanont K, et al. Candidemia following severe COVID-19 in hospitalised and critical ill patients: A systematic review and Meta-Analysis. Mycoses. 2024;67:e13798.","journal-title":"Mycoses"},{"key":"12479_CR22","unstructured":"WHO. WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action. Licence: CC BY-NC-SA 3.0 IGO. 2022."},{"key":"12479_CR23","doi-asserted-by":"publisher","unstructured":"Hoenigl M et al. COVID-19-associated fungal infections. Nature Microbiology 2022;7:1127\u20131140 Preprint at https:\/\/doi.org\/10.1038\/s41564-022-01172-2.","DOI":"10.1038\/s41564-022-01172-2"},{"key":"12479_CR24","doi-asserted-by":"publisher","unstructured":"Almudena JR, Lidia L, Nosocomial. COVID-19: a nationwide Spanish study. Gerontology 2023 https:\/\/doi.org\/10.1159\/000527711.","DOI":"10.1159\/000527711"},{"key":"12479_CR25","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14787210.2022.2011719","volume":"20","author":"S Khan","year":"2022","unstructured":"Khan S, Hasan SS, Bond SE, Conway BR, Aldeyab MA. Antimicrobial consumption in patients with COVID-19: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2022;20:749\u201372.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"12479_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijregi.2022.02.008","volume":"3","author":"S Budhiraja","year":"2022","unstructured":"Budhiraja S, et al. Secondary infections modify the overall course of hospitalized patients with COVID-19: a retrospective study from a network of hospitals across North India. IJID Reg. 2022;3:44\u201353.","journal-title":"IJID Reg"},{"key":"12479_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jiph.2021.02.001","volume":"14","author":"M Chedid","year":"2021","unstructured":"Chedid M, et al. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health. 2021;14:570\u20136.","journal-title":"J Infect Public Health"},{"key":"12479_CR28","first-page":"2","volume":"14","author":"EC Lingas","year":"2022","unstructured":"Lingas EC. Empiric antibiotics in COVID 19: A narrative review. Cureus. 2022;14:2\u20137.","journal-title":"Cureus"},{"key":"12479_CR29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3855\/jidc.18480","volume":"18","author":"E Ozyurt","year":"2024","unstructured":"Ozyurt E, Erman Daloglu A, Inanoglu K, Kavrut Ozturk N, Ozmen S. Bacterial and fungal secondary infections occurring in COVID-19 patients followed in intensive care: a retrospective study. J Infect Dev Ctries. 2024;18:350\u20134.","journal-title":"J Infect Dev Ctries"},{"key":"12479_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/pathogens12010117","volume":"12","author":"B Bedeni\u0107","year":"2023","unstructured":"Bedeni\u0107 B, et al. Multidrug-Resistant bacteria in a COVID-19 hospital in Zagreb. Pathogens. 2023;12:117.","journal-title":"Pathogens"},{"key":"12479_CR31","doi-asserted-by":"crossref","unstructured":"Kariyawasam RM et al. Antimicrobial resistance (AMR) in COVID-19 patients: a systematic review and meta-analysis (November 2019\u2013June 2021). Antimicrob Resist Infect Control 2022:11.","DOI":"10.1186\/s13756-022-01085-z"},{"key":"12479_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics12020312","volume":"12","author":"DA Toc","year":"2023","unstructured":"Toc DA, et al. A Tale of two pandemics: antimicrobial resistance patterns of Enterococcus spp. In COVID-19 era. Antibiotics. 2023;12:1\u201317.","journal-title":"Antibiotics"},{"key":"12479_CR33","doi-asserted-by":"crossref","unstructured":"Francino MP. Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. Front Microbiol 6, (2016).","DOI":"10.3389\/fmicb.2015.01543"},{"key":"12479_CR34","first-page":"4","volume":"14","author":"I Bahceci","year":"2022","unstructured":"Bahceci I, et al. Secondary bacterial infection rates among patients with COVID-19. Cureus. 2022;14:4\u201311.","journal-title":"Cureus"},{"key":"12479_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/ash.2023.425","volume":"3","author":"G Wu","year":"2023","unstructured":"Wu G, Lu J, Liu D, He Y. Characteristics and risk factors of secondary bacterial infections in COVID-19 patients. Antimicrob Stewardship Healthc Epidemiol. 2023;3:1\u20139.","journal-title":"Antimicrob Stewardship Healthc Epidemiol"},{"key":"12479_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5144\/0256-4947.2023.243","volume":"43","author":"K Binkhamis","year":"2023","unstructured":"Binkhamis K, et al. Prevalence of secondary infections and association with mortality rates of hospitalized COVID-19 patients. Ann Saudi Med. 2023;43:243\u201353.","journal-title":"Ann Saudi Med"},{"key":"12479_CR37","first-page":"1","volume":"59","author":"R Silaghi-dumitrescu","year":"2023","unstructured":"Silaghi-dumitrescu R, Patrascu I, Lehene M, Bercea I. Comorbidities of COVID-19 patients. Med (B Aires). 2023;59:1\u201316.","journal-title":"Med (B Aires)"},{"key":"12479_CR38","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1021\/acsptsci.2c00181","volume":"6","author":"S Chatterjee","year":"2023","unstructured":"Chatterjee S, et al. Association of COVID-19 with comorbidities: an update. ACS Pharmacol Transl Sci. 2023;6:334\u201354.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"12479_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s42399-021-01114-9","volume":"4","author":"AN Jamnani","year":"2022","unstructured":"Jamnani AN, Montazeri M, Mirzakhani M, Moosazadeh M, Haghighi M. Evaluation of bacterial coinfection and antibiotic resistance in patients with COVID-19 under mechanical ventilation. SN Compr Clin Med. 2022;4:4\u20138.","journal-title":"SN Compr Clin Med"},{"key":"12479_CR40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s10096-024-04755-5","volume":"43","author":"Y Duan","year":"2024","unstructured":"Duan Y, et al. Risk factors, outcomes, and epidemiological and etiological study of hospitalized COVID-19 patients with bacterial co-infection and secondary infections. Eur J Clin Microbiol Infect Dis. 2024;43:577\u201386.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"12479_CR41","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, china: a retrospective cohort study. Lancet. 2020;395:1054\u201362.","journal-title":"Lancet"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12479-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12479-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12479-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:59:46Z","timestamp":1781625586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12479-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12479"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12479-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7756601\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and with relevant regulations, approved protocol and good clinical practice. The study was approved by the HTD Ethics Committee (Number: 2630\/QD-BVBND), Oxford Tropical Research Ethics Committee (OxTREC Reference: 530\u2009\u2212\u200922), and the International Vaccine Institute (IVI) Institutional Review Board (IRB Number: 2022-010). This was a retrospective study involving no direct patient enrollment, for which the requirement for consent to participate was waived by the HTD Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}